News Releases

Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time   AUSTIN, Texas , June 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a

AUSTIN, Texas , May 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered

Abstracts feature data on ETBs against clinically validated targets including PD-L1, CTLA-4, SLAMF7 and CD45 AUSTIN, Texas ,, May 15, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the

AUSTIN, Texas , May 13, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,

AUSTIN, Texas , May 11, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies

AUSTIN, Texas , May 07, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (the “Company”) (Nasdaq: MTEM) announced today that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually due to the public health impact of the novel coronavirus outbreak (COVID-19) and to

AUSTIN, Texas , March 12, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies

AUSTIN, Texas , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,

Milestone Triggers $10 Million Payment to Molecular Templates AUSTIN, Texas , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary

Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships AUSTIN, Texas , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of